360 DigiTech, Inc. (QFIN)

Class Action & Lead Plaintiff Deadline: September 13, 2021

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against 360 DigiTech, Inc. ("360 DigiTech" or "the Company") (NASDAQ: QFIN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired 360 DigiTech securities between April 30, 2020 and July 7, 2021, inclusive (the “Class Period”). 

 

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

 

The complaint alleges the throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had been collecting personal information in violation of relevant People’s Republic of China ("PRC") laws and regulations; (2) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

A class action lawsuit has already been filed. You can review a copy of the Complaint and sign the certification form or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in 360 DigiTech you have until September 13, 2021 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.